Innocan's CBD Drug Eases Dog Arthritis, Eyes Human Pain Relief Next

HERZLIYA, Israel – February 09, 2026 – In a significant development for veterinary and potentially human medicine, Innocan Pharma Corporation has published robust clinical data demonstrating its long-acting cannabidiol (CBD) formulation provides substantial pain relief for dogs suffering from osteoarthritis. The peer-reviewed study, published in the esteemed journal Frontiers in Veterinary Science, shows that a single injection of the company's LPT-CBD treatment offered up to four weeks of improved mobility and reduced pain, significantly outperforming a placebo.

The findings represent a critical validation of Innocan’s drug delivery technology and have emboldened the company to pursue regulatory approval not only for companion animals but also for human pain management, a move that could position it as a key player in the search for non-opioid pain solutions.

A Leap Forward in Veterinary Pain Management

The study, titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs," provides compelling evidence for pet owners and veterinarians seeking effective, long-term pain control for arthritic canines. The research employed a rigorous randomized, blinded, placebo-controlled, crossover design—a gold standard in clinical trials—to assess the treatment's efficacy in eight client-owned dogs with naturally occurring osteoarthritis.

The results were striking. According to owner reports, 100% of dogs showed improved function and behavior after receiving the LPT-CBD injection, compared to just 25% following the placebo. Veterinarian assessments confirmed these observations, recording a statistically significant reduction in both lameness and pain. A single subcutaneous injection was able to maintain measurable concentrations of CBD in the dogs' plasma for up to four weeks, corroborating the long-lasting clinical benefits.

"LPT-CBD has been repeatedly demonstrated to have a pain relief effect across multiple efficacy studies in dogs, goats, and other animals," said Professor Chezy Barenholz, Head of Innocan's Advisory Board. "However, this study is particularly important because it shows the clear advantages of LPT-CBD over the liposomal placebo."

Critically, the treatment was well-tolerated. The only adverse events noted were minor and self-resolving, including a transient fever and temporary swelling at the injection site, which disappeared within days without intervention. This favorable safety profile is a key advantage over some traditional pain medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), which can carry risks of gastrointestinal and kidney-related side effects with long-term use.

Navigating a Crowded and Complex Market

Innocan's achievement is notable not just for its scientific merit, but also for its strategic approach in a crowded market. The pet wellness industry is flooded with CBD products, from oils to treats, most of which are sold as unregulated supplements with little to no clinical data to support their claims. The FDA has not approved any CBD products for animal use and has issued warnings about unapproved drugs making therapeutic claims.

By contrast, Innocan is pursuing the stringent, costly, but ultimately more valuable path of a pharmaceutical drug. Publishing in a reputable, peer-reviewed journal like Frontiers in Veterinary Science—a Q1 journal with a high impact factor—lends significant scientific credibility to its LPT-CBD platform. This differentiates the company's product as a potential prescription medicine backed by robust science, rather than just another supplement.

While the study's sample size of eight dogs is typical for an early-stage trial and will require confirmation in larger cohorts, the strength of the crossover design and the statistical significance of the results provide a powerful proof-of-concept. This data is the foundation for the company's ongoing discussions with the FDA's Center for Veterinary Medicine (CVM) to formalize a development and approval pathway.

The Bridge to Human Health

Perhaps the most compelling aspect of Innocan’s announcement is the clear ambition to translate its veterinary success into human therapeutics. The global search for effective, non-addictive pain management solutions has intensified amid the ongoing opioid crisis, creating a massive potential market for a long-acting, non-opioid analgesic.

Innocan has revealed it is leveraging the positive canine data to engage with the FDA's human analgesic and anesthetic department. This dual-track strategy, targeting both veterinary and human markets, is an ambitious but potentially powerful approach. Success in animal models is a crucial prerequisite for human trials, and the strong safety and efficacy profile demonstrated in dogs significantly de-risks the future development path for human applications.

Dr. Eyal Kalo, Vice President of Research and Development, commented on this potential. "We are encouraged by these results, particularly given LPT-CBD's potential as a long-acting approach to pain management in both veterinary and human settings," he stated. "We have initiated ongoing discussions with FDA... to support the advancement of LPT-CBD across both markets."

The company’s LPT platform uses liposomes—microscopic fat bubbles—to encapsulate synthetic CBD, allowing for a controlled, sustained release over an extended period. This technology addresses a key challenge in drug delivery: maintaining a stable, therapeutic level of a drug in the body without requiring frequent dosing, thereby improving patient compliance and potentially enhancing efficacy.

A Strategic Bet for a Biotech Pioneer

For an R&D-stage company like Innocan Pharma, which operates on the Canadian Securities Exchange (CSE), Frankfurt Stock Exchange (FSE), and the OTCQB market, this publication is more than just a scientific achievement; it is a critical business milestone. Such peer-reviewed validation is the currency of the biotech world, essential for attracting investment, securing partnerships, and increasing company valuation.

Like many biotech firms, Innocan operates at a loss while investing heavily in research. This successful study provides a tangible return on that investment, demonstrating that its core technology works as intended. It signals to the market that the company may possess a valuable asset with significant commercial potential in both the multi-billion-dollar animal health and human pain management sectors.

While the road to commercialization remains long and requires navigating the complex FDA regulatory landscape for both animals and humans, Innocan has laid a strong scientific foundation. The company's next steps in advancing its discussions with regulatory bodies will be closely watched by pet owners, patients, and investors alike, all hoping that this promising technology can fulfill its potential to alleviate chronic pain.